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ampliﬁed breast cancer cells
Eric Dietel1, Alexander Brobeil1,2, Claudia Tag1, Stefan Gattenloehner2 and Monika Wimmer1
Abstract
Breast cancer is the most common female cancerous disease and the second most cause of cancer death in women.
About 20–30% of these tumors exhibit an ampliﬁcation of the HER2/ErbB2 receptor, which is coupled to a more
aggressive and invasive growth of the cancer cells. Recently developed tyrosine kinase inhibitors and therapeutic
antibodies targeting the HER2 receptor improved the overall survival time compared with sole radio- and
chemotherapy. Upcoming resistances against the HER2-targeted therapy make a better understanding of the receptor
associated downstream pathways an absolute need. In earlier studies, we showed the involvement of Protein Tyrosine
Phosphatase Interacting Protein 51 (PTPIP51) in the mitogen-activated protein kinase (MAPK) pathway. The MAPK
pathway is one of the most frequently overactivated pathways in HER2-ampliﬁed breast cancer cells. This study is
aimed to elucidate the effects of four different TKIs on the interactome of PTPIP51, namely with the receptors EGFR
and HER2, 14-3-3/Raf1 (MAPK pathway), its regulating enzymes, and the mitochondria-associated interaction partners
in HER2 breast cancer cell lines (SK-BR3 and BT474) by using the Duolink proximity ligation assay, immunoblotting and
knockdown of PTPIP51. Inhibition of both EGFR and HER2/ErbB2R shifted PTPIP51 into the MAPK pathway, but left the
mitochondria-associated interactome of PTPIP51 unattended. Exclusively inhibiting HER2/ErbB2 by Mubritinib did not
affect the interaction of PTPIP51 with the MAPK signaling. Selective inhibition of HER2 induced great alterations of
mitochondria-associated interactions of PTPIP51, which ultimately led to the most-effective reduction of cell viability of
SK-BR3 cells of all tested TKIs. The results clearly reveal the importance of knowing the exact mechanisms of the
inhibitors affecting receptor tyrosine kinases in order to develop more efﬁcient anti-HER2-targeted therapies.
Introduction
The identiﬁcation of targetable signal nodes and
protein–protein interactions is of utmost interest for the
development of novel drugs for the treatment of cancer
and other diseases such as neurodegenerative diseases.
The human EGFR-related receptor 2 (HER2) oncogene/
oncoprotein represents a perfect example of such a
treatable target. The ampliﬁcation of HER2 in breast
cancer leads to severe alterations in growth and pro-
liferation signaling, e.g., mitogen-activated protein kinase
(MAPK) signaling, resulting in a more aggressive and
invasive growth of the tumor1,2. Owing to the develop-
ment of small molecules and therapeutic antibodies
against this target, the treatment of HER2-ampliﬁed
breast cancer made great progress. The combination of
anthracyclin-based and non-anthracyclin-based che-
motherapies with trastuzumab, a HER2-targeted ther-
apeutic antibody, led to disease-free survival rates at 5
years of 81–84% compared with 75% without trastuzumab
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in HER2-positive early-stage breast cancer3. The already
clinically established tyrosine kinase inhibitor Lapatinib,
which targets epidermal growth factor receptor (EGFR)
and HER2, improved the time to progression from
4.4 months to 8.4 months in a capecetabin vs. capeceta-
bine plus lapatinib setting4.
HER2, also known as ErbB2 (erythroblastosis homolog
B2), is an orphan receptor. It belongs to the Her family
like the EGFR. As there is no identiﬁed ligand of the HER2
receptor, the downstream signaling is activated by
autophosphorylation through the formation of homo-
dimers or heterodimers with other members of the Her
family. HER2 signaling is channeled into the MAPK and
PI3K/Akt signaling leading to proliferation, growth, and
survival of the cell.
In consequence of its upstream position, the blockage of
the growth and proliferation signaling on the HER2 level
can be bypassed and the effect of the small molecule
inhibitor or the therapeutic antibody, respectively, is
omitted5. In order to develop the most-effective drugs, it
is crucial to understand regulatory interactions in MAPK
and PI3K/Akt signaling downstream of the receptor.
One of the MAPK pathway regulators is the protein
tyrosine phosphatase interacting protein 51 (PTPIP51).
PTPIP51 is expressed in many highly differentiated tissues
and often deregulated in cancer. It is involved in many
diverse cellular functions including cell growth, differ-
entiation, proliferation, and apoptosis. The panel of
interaction partners ranges from MAPK-associated pro-
teins (EGFR, Raf1) over scaffolding proteins (14.3.3) to
NFkB signaling proteins (RelA, IkB) and mitosis-
associated proteins (CGI-99, Nuf2)6–8.
PTPIP51 plays an essential role in the development of
several cancer types. For example, the malignancy of
glioblastomas is correlated to the expression of PTPIP519.
In basal cell and squamous cell carcinoma, the expression
pattern of PTPIP51 is altered10. In prostate cancer,
hypomethylation of the PTPIP51 promoter region results
in an increased expression of the protein11. Malignant
blasts of acute myeloid leukemia (AML) exhibit PTPIP51
expression in contrast to healthy bone marrow cells. The
interaction of PTPIP51 with the MAPK pathway in AML
blasts is inhibited as a result of its highly phosphorylated
Tyr176 residue12,13.
PTPIP51 exerts its regulating effect on the MAPK
pathway on Raf1 level via the scaffolding protein 14-3-3.
The recruitment of PTPIP51 into the MAPK signaling
leads to an activation of the MAPK pathway7. A well-
titrated signal is a prerequisite for an optimal cellular
function. Therefore, the formation of the PTPIP51/14-3-
3/Raf1 complex is tightly regulated by kinases and phos-
phatases12,14,15. One of the crucial spots for this regulation
is the tyrosine residue 176 of PTPIP51. Its phosphoryla-
tion results in a break-up of the PTPIP51/14.3.3/Raf1
complex and hence an omission of the MAPK signaling
stimulation14. The phosphorylation of the Tyr176 residue
is under the control of the EGFR and other kinases, such
as the. c-Src kinase. Dephosphorylation is mainly per-
formed by PTP1B15.
PTPIP51 is not only regulator of MAPK signaling, but
also essential part of the communication site between
mitochondria and endoplasmic reticulum (ER)16,17. These
sites are called mitochondrial-associated ER membranes
(MAM) and are deﬁned by close contacts (10–30 nm) of
the organelles. One of the interactions, which stabilizes
these contact sites is the interaction of PTPIP51 and
VAPB18. The communication is essential for the regula-
tion of calcium homeostasis, apoptosis, autophagy, and
many more processes, which are crucial for cell survival
and cell death19–21. The MAMs are also signaling hubs for
mammalian target of rapamycin (mTOR) and protein
kinase B(Akt) signaling22. Alterations of these precisely
regulated contact sites immensely affect the fate of the
cell.
This study analyzed the effects of four different tyrosine
kinase inhibitors (TKI) on the MAPK pathway, Akt sig-
naling, and MAM-related interactome of PTPIP51 and in
addition, these effects were correlated to the viability of
the TKI-treated cells. We used Geﬁtinib, a selective EGFR
inhibitor, Mubritinib, a selective HER2 inhibitor23, Lapa-
tinib, an already clinically established EGFR and HER2
inhibitor, and Neratinib, a further developed EGFR and
HER2 inhibitor.
Results
Selective inhibition of HER2 strongly affects the
mitochondrial metabolism in SK-BR3 cells
To monitor the effects of selective and simultaneous
inhibition of EGFR and HER2 on mitochondrial
metabolism, 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide (MTT) assays were performed.
SK-BR3 and BT474 cells were treated over 24 h, 48 h, or
72 h with the indicated concentration of TKIs. All cells
were incubated with the same amount of dimethyl sulf-
oxide (DMSO) in order to exclude potential toxic effects
of DMSO. The selective inhibition of HER2 by Mubriti-
nib, especially 10 µM, reduced the mitochondrial meta-
bolic rate of SK-BR3 cells by ~ 40%, when treated for 24 h
(Fig. 2c). The effect even increased for longer incubation
times (reduction of the mitochondrial metabolic rate of ~
60% for 10 µM Mubritinib for 48 h or 72 h). BT474 cells
showed a likewise behavior, when treated with the selec-
tive HER2 inhibitor Mubritinib. Although, the reduction
of mitochondrial metabolic rate was not as severe as for
the SK-BR3 cells (Fig. 2d).
The dual inhibition of EGFR and HER2 by Lapatinib
and Neratinib also resulted in a signiﬁcantly diminished
mitochondrial metabolism but reduced the rel.
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Absorbance, which indicates the metabolic activity, only
~ 10–20% for SK-BR3 cells and 24 h incubation time
(Figs. 1c and 2a). If incubated for 48 h or 72 h with
Lapatinib or Neratinib, the reduction of the mitochondrial
metabolic rate in SK-BR3 cells increased for both inhibi-
tors. Noteworthy, application of Neratinib led to stronger
reduction of mitochondrial metabolism compared with
the application of Lapatinib (5 µM Lapatinib for 72 h,
reduction of ~ 40%; 200 nM Neratinib for 72 h, reduction
of ~ 55%). Treatment of BT474 cells with dual kinase
inhibitors, Lapatinib and Neratinib, induced a reduction
of mitochondrial metabolic rate of ~ 50% for the highest
applied concentration and incubation time of 72 h (Fig.
1d, Fig. 2b).
The selective inhibition of EGFR by Geﬁtinib did not
alter the mitochondrial metabolism of SK-BR3 cells if
Fig. 1 Mitochondrial metabolic rate under the inﬂuence of Geﬁtinib and Lapatinib. SK-BR3 cells treated with the indicated concentrations of
Geﬁtinib over a time period of 24 h, 48 h, or 72 h (a). BT474 cells treated with the indicated concentrations of Geﬁtinib over a time period of 24 h, 48 h,
or 72 h (b). SK-BR3 cells treated with the indicated concentrations of Lapatinib over a time period of 24 h, 48, or 72 h (c). BT474 cells treated with the
indicated concentrations of Lapatinib over a time period of 24 h, 48 h, or 72 h (d). (N= 3)
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incubated for 24 h (Fig. 1a). Longer incubation times,
highly signiﬁcant, reduced the mitochondrial metabolism
for all applied concentrations. Selective inhibition of
EGFR with Geﬁtinib in BT474 cells induced a reduction of
mitochondrial metabolism for all concentrations and
incubation times (5 µM Geﬁtinib for 48 h or 72 h,
reduction of ~ 50%) (Fig. 1b).
Noteworthy, all applied TKIs displayed a much higher
reduction of metabolic activity in BT474 cells compared
with SK-BR3 cells when treated for 24 h.
Fig. 2 Mitochondrial metabolic rate under the inﬂuence of Neratinib and Mubritinib. SK-BR3 cells treated with the indicated concentrations of
Neratinib over a time period of 24 h, 48 h, or 72 h (a). BT474 cells treated with the indicated concentrations of Neratinib over a time period of 24 h,
48 h, or 72 h (b). SK-BR3 cells treated with the indicated concentrations of Mubritinib over a time period of 24 h, 48 h or 72 h (c). BT474 cells treated
with the indicated concentrations of Mubritinib over a time period of 24 h, 48 h, or 72 h (d). (N= 3)
Dietel et al. Oncogenesis  (2018) 7:64 Page 4 of 14
Oncogenesis
Selective inhibition of EGFR leads to a formation of EGFR-
HER2 dimers
For the examination of the PTPIP51 interactome under
the inﬂuence of TKIs, we monitored 12 different
protein–protein interactions. In order to track down the
precise mode of action, we determined the formation of
EGFR-HER2 dimers. Cells were treated and ﬁxed as
mentioned above. Subsequently, the cells were incubated
with primary antibodies raised against EGFR and HER2,
followed by Duolink proximity ligation assay (precisely
described in Materials and Methods).
The selective inhibition of HER2 by Mubritinib did not
affect the numbers of EGFR/HER2 dimers in SK-BR3
cells. Whereas the EGFR-targeted TKIs induced an
enhanced formation of EGFR/HER2 dimers (Fig.3c, Sup-
plementary Figure 1). All applied concentrations of
Geﬁtinib induced an augmented formation of EGFR/
HER2 dimers (1 µM and 2 µM p < 0.01, 5 µM p < 0.0001)
(Supplementary Figure 1A). The same enhancement was
observed for Lapatinib (1 µM, 2 µM, and 5 µM p < 0.0001)
(Supplementary Figure 1B) and Neratinib (2 nM p <
0.0001, 20 nM p < 0.01, 200 nM p < 0.05) (Supplementary
Figure 1D).
Noteworthy, in BT474 cells only the application of
Geﬁtinib led to a signiﬁcant increase of EGFR/HER2
dimers (5 µM Geﬁtinib p < 0.01) (Fig. 3c). All other
applied TKI did not signiﬁcantly alter the number of
EGFR/HER2 dimers.
We also monitored the interactions of PTPIP51 with
EGFR and HER2, respectively. The application of EGFR-
targeted TKIs, Geﬁtinib, Lapatinib, and Neratinib,
induced an enhanced interaction of PTPIP51 with EGFR
and HER2. The selective inhibition of HER2 with
Mubritinib only increased the interaction of PTPIP51 and
HER2 (0.1 µM p < 0.05, 1 µM, and 10 µM p < 0.0001)
(Supplementary Figure 2G). The interaction of EGFR and
PTPIP51 remained unaffected (Supplementary Figure
2A). Likewise results were seen for BT474 cells (Fig. 3a, b)
EGFR-targeted TKIs promote the formation of the
PTPIP51–14.3.3-Raf1-complex
To examine the effects on MAPK-related interactions of
PTPIP51 under the inﬂuence of TKI, we measured the
interactions of PTPIP51 with 14.3.3 and Raf1, respectively.
The inhibition of EGFR by Geﬁtinib, Lapatinib, or Ner-
atinib induced the formation of the PTPIP51–14.3.3-Raf1-
complex in SK-BR3 cells. Application of 2 µM and 5 µM
Geﬁtinib applied for 24 h highly signiﬁcant enhanced the
interaction of PTPIP51 and 14.3.3 (p < 0.0001) (Fig. 4b,
Supplementary Figure 3A). The complex formation of
PTPIP51/Raf1 was augmented in the same manner (2 µM
and 5 µM for 24 h p < 0.0001) (Supplementary Figure 3E).
Fig. 3 Interaction of EGFR, HER2, and PTPIP51 under Geﬁtinib, Lapatinib, Neratinib, and Mubritinib treatment. Interaction of EGFR and
PTPIP51 in SK-BR3 and BT474 cells treated with 5 µM Geﬁtinib, 5 µM Lapatinib, 200 nM Neratinib, or 10 µM Mubritinib for 24 h (a). Interaction of HER2
and PTPIP51 in SK-BR3 and BT474 cells treated with 5 µM Geﬁtinib, 5 µM Lapatinib, 200 nM Neratinib, or 10 µM Mubritinib for 24 h (b). Interaction of
EGFR and HER2 in SK-BR3 and BT474 cells treated with 5 µM Geﬁtinib, 5 µM Lapatinib, 200 nM Neratinib, or 10 µM Mubritinib for 24 h (c). (N= 3)
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Application of Lapatinib for 24 h induced likewise
observations (PTPIP51/14.3.3: 2 µM p < 0.001, 5 µM p <
0.0001; PTPIP51/Raf1 2 µM and 5 µM p < 0.0001) (Sup-
plementary Figure 3B and F). Noteworthy, the complex
formation of PTPIP51/14.3.3/Raf1 under Neratinib was
measurable for 24 h and 48 h (PTPIP51/14.3.3: 24 h
20 nM p < 0.001, 200 nM p < 0.0001; 48 h 2 nM p < 0.05,
20 nM, and 200 nM p < 0.0001; PTPIP51/Raf1: 24 h
200 nM p < 0.0001; 48 h 2 nM, 20 nM, and 200 nM p <
0.0001) (Supplementary Figure 3D and H). On the con-
trary, selective inhibition of HER2 did not affect the
interaction of PTPIP51 and Raf1 (Fig. 4a, b, Supplemen-
tary Figure 3H). These ﬁndings are corroborated by the
observed changes of PTPIP51 Tyr176 phosphorylation.
Dephosphorylation of Tyr176 of PTPIP51 is a prerequisite
for the formation of the PTPIP51–14.3.3-Raf1-complex.
The application of TKIs targeting EGFR resulted in a
reduced phosphorylation level, whereas selective HER2
inhibition even enhanced the Tyr176 phosphorylation
status (Fig. 5, Supplementary Figure 7).
The observations of formation of the PTPIP51/Raf1/
14.3.3 complex under EGFR and/or HER2 inhibition in
BT474 slightly differed. As seen in SK-BR3 cells, all
EGFR-targeted TKI (Geﬁtinib, Lapatinib, and Neratinib)
induced an increase of PTPIP51 and Raf1 interaction
(5 µM Geﬁtinib p < 0.001, 5 µM Lapatinib, p < 0.0001,
Neratinib p < 0.0001). Also Mubritinib as a selective HER2
inhibitor enhanced the interaction of PTPIP51 and Raf1
(10 µM Mubritinib p < 0.0001) (Fig. 4a). In addition, the
interaction of PTPIP51 and 14.3.3 in BT474 cells is dif-
ferently altered compared with the SK-BR3 cells. The
application of Geﬁtinib, Lapatinib, and Mubritinib
induced an increase of PTPIP51/14.3.3 interaction in
BT474 (5 µM Geﬁtinib p < 0.01, 5 µM Lapatinib p < 0.001,
10 µM Mubritinib p < 0.001). In contrast to the SK-BR3
cells, Neratinib did not enhance the interaction of
PTPIP51 and 14.3.3 in BT474 cells (Fig. 4b).
Besides, EGFR, which phosphorylates the Tyr176 resi-
due, PTPIP51 phosphorylation levels are also equilibrated
by the activity of the tyrosine kinase c-Src and the phos-
phatase PTP1B. All applied TKIs enhanced the interaction
of PTPIP51 and c-Src in SK-BR3 cells (Geﬁtinib: 24 h
5 µM p < 0.0001; Lapatinib: 24 h 1 µM p < 0.05, 2 µM p <
0.01, 5 µM p < 0.0001, 48 h 2 µM p < 0.05; Neratinib: 24 h
2 nM p < 0.01, 20 nM p < 0.05, 200 nM p < 0.0001, 48 h
2 nM, and 200 nM p < 0.0001; Mubritinib: 24 h 1 µM p <
0.01, 10 µM p < 0.0001, 48 h 1 µM p < 0.001, 10 µM p <
0.0001) (Fig. 4c, Supplementary Figure 4A, B, C and D). In
accordance to the differing alterations of PTPIP51/Raf1
and PTPIP51/14.3.3 interactions seen in BT474 cells, also
the interaction of PTPIP51/c-Src and PTPIP51/PTP1B
were affected differently. Application of Geﬁtinib or
Mubritinib to BT474 cells reduced the interaction of
PTPIP51 and c-Src (5 µM Geﬁtinib p < 0.01, 10 µM
Mubritinib p < 0.01) (Fig. 4c). Lapatinib and Neratinib did
not signiﬁcantly affect the interaction of PTPIP51/c-Src in
BT474 cells (Fig. 4c). The interaction of PTPIP51 with its
main phosphatase PTP1B was not affected by the appli-
cation of Geﬁtinib, Lapatinib, Neratinib, or Mubritinib in
BT474 cells (Fig. 4d).
Yet, effects on the interaction of PTPIP51 with PTP1B
in SK-BR3 differed. The application of Geﬁtinib and
Lapatinib induced an increase of interaction after 48 h
incubation time (Geﬁtinib: 1 µM p < 0.0001, 2 µM
p < 0.01, 5 µM p < 0.001; Lapatinib: 1 µM, and 2 µM p <
0.0001, 5 µM p < 0.05) (Fig. 3d, Supplementary Figure 4E
and F). On the contrary, Neratinib diminished the
PTPIP51-PTP1B interaction (24 h: 20 nM p < 0.01,
200 nM p < 0.0001; 48 h: 20 nM, and 200 nM p < 0.001)
(Supplementary Figure 4H). Mubritinib did not affect this
interaction at all (Supplementary Figure 4G).
In order to determine the activation status of the MAPK
signaling, pMAPK blots were performed. The inhibition
of EGFR by Geﬁtinib, Lapatinib, or Neratinib led to a
complete shutdown of MAPK signaling. Mubritinib
induced an activation of MAPK signaling (Fig. 5).
Inhibition of the EGFR and/or HER2 affects the tether
between ER and mitochondria
The inhibition of EGFR led to an enhanced binding of
VAPB and PTPIP51 in both cell lines(Geﬁtinib: 1 µM and
5 µM p < 0.01, 2 µM p < 0.001; Lapatinib: 1 µM and 5 µM
p < 0.0001, 2 µM p < 0.05, Neratinib: 2 nM p < 0.0001)
(Fig. 4e, Supplementary Figure 5A, B and D) in contrast to
the selective inhibition of HER2, which led to a reduction
of PTPIP51-VAPB interaction in SK-BR3 cells if the
highest concentration of Mubritinib was applied (10 µM
p < 0.001) (Fig. 4e, Supplementary Figure 5C). Treatment
of the BT474 cells with Mubritinib did not signiﬁcantly
alter the number of interactions (Fig. 4e). The interaction
of PTPIP51 and VAPB is regulated by the GSK3B. Lapa-
tinib and Mubritinib induced a highly signiﬁcant increase
of the PTPIP51-GSK3B interaction in SK-BR3 cells
(Lapatinib: 2 µM and 5 µM p < 0.01; Mubritinib 0.1 µM p
< 0.05, 1 µM and 10 µM p < 0.0001) (Fig. 4f, Supplemen-
tary Figure 5F and G), whereas Geﬁtinib and Neratinib did
not affect the PTPIP51-GSK3B interaction (Fig. 4f, Sup-
plementary Figure 5E and H). In BT474 cells only the
application of Mubritinib induced a signiﬁcant increase of
PTPIP51/GSK3B interactions (10 µMMubritinib p < 0.05)
(Fig. 4f).
Inhibition of EGFR and HER2 alters the interactions of
PTPIP51 with Akt and PKC
We examined the interaction of PTPIP51 with the
kinase PKC and Akt. The interaction of PTPIP51 and Akt
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Fig. 4 (See legend on next page.)
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in both cell lines increased when Mubritinib was added
(SK-BR3 10 µM Mubritinib p < 0.01; BT474 10 µM
Mubritinib p < 0.05) (Fig. 4g). All other tested TKI did not
signiﬁcantly alter the interaction of PTPIP51 and Akt (Fig.
4g). The interaction of PKC and PTPIP51 signiﬁcantly
increased in both cell lines if Lapatinib or Mubritinib were
applied (SK-BR3 5 µM Lapatinib p < 0.001, 10 µM
Mubritinib p < 0.0001; BT474 5 µM Lapatinib p < 0.001,
10 µM Mubritinib p < 0.001) (Fig. 4h). Application of
Geﬁtinib or Neratinib did not induce a signiﬁcant
alteration of PTPIP51/PKC interaction in SK-BR3 cell,
whereas the same TKI led to an signiﬁcant increase of the
interaction in BT474 cells (5 µM Geﬁtinib p < 0.05,
200 nM Neratinib p < 0.0001) (Fig. 4h).
In order to determine the activity of Akt signaling, as an
indicator of mTORC2 activity, pSer 473 Akt immunoblots
were performed. The inhibition of EGFR led to an almost
abolished Akt signaling. Whereas, Mubritinib induced an
activation of Akt signaling as determined by its Ser473
phosphorylation (Fig. 5).
PTPIP51 plays an essential part in the mubritinib-induced
Akt activation
To precisely determine the importance of PTPIP51 in
these complex regulations, we performed a shRNA
knockdown experiment of PTPIP51 in SK-BR3 cells. The
exact description of the procedure is mentioned in the
Materials and Methods section. We used four different
constructs for the knockdown of PTPIP51. For evaluation
we only used the construct 4 since it showed the most-
effective knockdown of PTPIP51 (Fig. 6a, c). The knock-
down of PTPIP51 only slightly altered the activation level
of the MAPK pathway as indicated by the phosphoryla-
tion of ERK1/2 (pMAPK) if no tyrosine kinase inhibitor
was applied(Fig. 6a, b). Application of the tested TKI to
the PTPIP51 knockdown SK-BR3 cells only slightly
altered the activation of MAPK pathway (Fig. 6a, b).
Knockdown of PTPIP51 induced a strongly reduced Akt
activation seen under Mubritinib treatment (Fig. 6a, d).
All other tested TKI also showed a reduced Akt activation
in the PTPIP51 knockdown setting (Fig. 6d).
Selective inhibition of c-Src alters the ternary complex of
PTPIP51/HER2/c-Src
For the precise examination of the ternary complex
PTPIP51/c-Src/HER2 we used Dasatinib for the selective
inhibition of c-Src. Interactions were monitored using the
Duolink proximity ligation assay (precisely described in
Materials and Methods). Treatment of SK-BR3 cells with
Dasatinib did not signiﬁcantly alter the interaction of
PTPIP51 and c-Src (Fig. 7a). Application of Dasatinib
induced an signiﬁcant increase of PTPIP51/HER2 inter-
action for all applied concentrations (0.1 µM p < 0.001,
1 µM p < 0.05, 10 µM p < 0.05) (Fig. 7b). Interaction of c-
Src and HER2 was signiﬁcantly enhanced if 1 µM or
10 µM Dasatinib were applied (1 µM p < 0.0001, 10 µM p
< 0.001) (Fig. 7c).
Discussion
During the last decades, targeted therapy of malignant
diseases experienced a rapid development, e.g., the suc-
cessful establishment of HER2-targeted therapy using the
Fig. 4 MAPK and MAM-related interactome of PTPIP51 under Geﬁtinib, Lapatinib, Neratinib, and Mubritinib treatment. Interaction of Raf1
and PTPIP51 in SK-BR3 and BT474 cells treated with 5 µM Geﬁtinib, 5 µM Lapatinib, 200 nM Neratinib, or 10 µM Mubritinib for 24 h (a). Interaction of
14.3.3 and PTPIP51 in SK-BR3 and BT474 cells treated with 5 µM Geﬁtinib, 5 µM Lapatinib, 200 nM Neratinib, or 10 µM Mubritinib for 24 h (b).
Interaction of c-Src and PTPIP51 in SK-BR3 and BT474 cells treated with 5 µM Geﬁtinib, 5 µM Lapatinib, 200 nM Neratinib, or 10 µM Mubritinib for 24 h
(c). Interaction of PTP1B and PTPIP51 in SK-BR3 and BT474 cells treated with 5 µM Geﬁtinib, 5 µM Lapatinib, 200 nM Neratinib, or 10 µM Mubritinib for
24 h (d). Interaction of VAPB and PTPIP51 in SK-BR3 and BT474 cells treated with 5 µM Geﬁtinib, 5 µM Lapatinib, 200 nM Neratinib, or 10 µM Mubritinib
for 24 h (e). Interaction of GSK3B and PTPIP51 in SK-BR3 and BT474 cells treated with 5 µM Geﬁtinib, 5 µM Lapatinib, 200 nM Neratinib, or 10 µM
Mubritinib for 24 h (f). Interaction of Akt and PTPIP51 in SK-BR3 and BT474 cells treated with 5 µM Geﬁtinib, 5 µM Lapatinib, 200 nM Neratinib, or
10 µM Mubritinib for 24 h (g). Interaction of PKC and PTPIP51 in SK-BR3 and BT474 cells treated with 5 µM Geﬁtinib, 5 µM Lapatinib, 200 nM Neratinib,
or 10 µM Mubritinib for 24 h (h). (N= 3)
Fig. 5 Phosphorylation status of the Tyr176 residue of PTPIP51,
activation status of MAPK signaling and activation status of Akt
signaling under Geﬁtinib, Lapatinib, Neratinib, and Mubritinib
treatment. Immunobloting of phospho Tyr176 PTPIP51. Cell were
treated with the indicated concentrations of the four different TKIs.
The multiple bands are due to the different isoforms of PTPIP51. For
evaluation only the 52 kDa isoform of PTPIP51 was used. The
immunoblots were normalized to the stain-free blot
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humanized monoclonal antibody Trastuzumab or TKI-
like Lapatinib24,25. Yet, an increasing number of reports
dealing with resistances to the applied targeted therapy
were published26 The application of Trastuzumab results
in a downregulation of the HER2 receptor itself, modiﬁed
heterodimerization, and (de-) activation of associated
signaling pathways27. In Trastuzumab resistant cancer
cells, signaling molecules comprising PI3K and Akt as
well as PTEN are dysregulated26. The overexpression and
activation of the non-membrane tyrosine kinase c-Src was
identiﬁed as a further cause for the development of
resistances against HER2-targeted therapy in breast
cancer cells28. Interestingly, the same pathways play a
critical role in TKI resistance of breast cancer cells27.
In this context, the precise understanding of the
downstream effects of EGFR and HER2 TKI is crucial to
identify the affected signaling hubs and protein–protein
interactions. Forming homodimers and heterodimers with
EGFR and HER3, the receptor signaling of HER2 is cou-
pled for example to the MAPK pathway, to PI3K and Akt
signaling1. Of note, the investigated PTPIP51 represents a
key player in MAPK signaling by interfering on Raf1
level7,14,15. The spontaneously immortalized keratinocyte
cell line HaCaT displays a speciﬁc regulation and inter-
action pattern of PTPIP51 with the signaling molecules of
Fig. 6 shRNA knockdown of PTPIP51 in SK-BR3 cells. Immunoblots of PTPIP51, pMAPK, and pAkt of shRNA knockdown of PTPIP51 in SK-BR3 cells
treated with 5 µM Geﬁtinib, 5 µM Lapatinib, 200 nM Neratinib, or 10 µM Mubritinib for 24 h (a). Evaluation of pMAPK immunoblots (b). Evaluation of
pAkt immunoblots (c). Evaluation of PTPIP51 protein immunoblots (d). The immunoblots were normalized to the β-Actin level
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the MAPK pathway15 If stimulated by EGF, PTPIP51
interaction with the EGFR is increased accompanied by a
higher phosphorylation status of the tyrosine 176. The
mechanism prevents PTPIP51 to interact with Raf1 and
therefore to over-activate the MAPK pathway15. More-
over, PTP1B (dephosphorylates tyrosine 176 residue of
PTPIP51), PKA and PKC (phosphorylate serine 212 resi-
due of PTPIP51) interactions are augmented to maintain a
basal interaction with and stimulation of Raf1 by
PTPIP5115. The inhibition of the EGFR by Geﬁtinib in
HaCaT cells induced an increasing interaction of
PTPIP51 with 14-3-3 and Raf1 also maintaining a basal
level of MAPK activity probably for cell survival15.
Interestingly, after 48 h incubation the inhibition of the
EGFR in SK-BR3 and BT474 cells by Geﬁtinib, Lapatinib,
and Neratinib, regardless whether or not the HER2
receptor was inhibited as well, led to a recruitment of
PTPIP51 into MAPK signaling on Raf1 level particularly
paralleled by the observed decrease in Tyr176 phos-
phorylation of PTPIP51 as seen in SK-BR3 immunoblots.
In addition, the loss of Tyr176 phosphorylation was
accompanied by an increased interaction of PTPIP51 and
PTP1B. This interaction also facilitates the interaction of
PTPIP51 with Raf1 contributing to the minimal MAPK
activity of SK-BR3 cells. Therefore, we conclude that the
regulatory function of PTPIP51 on the MAPK pathway is
also present in both HER2-positive breast cancer cell lines
SK-BR3 and BT474.
However, the tyrosine phosphorylation of PTPIP51 is
still observed even though on a very low level. Inhibition
of EGFR induced an enhanced interaction of PTPIP51
with the non-receptor tyrosine kinase c-Src in SK-BR3
cells, which partially compensates the inhibited EGFR
kinase activity. c-Src plays a pivotal compensatory role in
the loss of EGFR kinase activity in breast cancer cells and
plays a crucial role in the resistance mechanism against
EGFR family targeting TKI29. Interestingly, the applica-
tion of EGFR/HER2-targeted TKI to the BT474 cells did
not induce an enhancement of PTPIP51/c-Src interaction.
This completely opposes the known regulations of
PTPIP51, since the inhibition of EGFR is normally par-
alleled by an increase in PTPIP51/c-Src interaction.
Fig. 7 PTPIP51/HER2/c-Src interactome under selective inhibition of c-Src in SK-BR3 cells. Interaction of PTPIP51 and c-Src in SK-BR3 cells
treated with the indicated concentrations of Dasatinib over 24 h (a). Interaction of PTPIP51 and HER2 in SK-BR3 cells treated with the indicated
concentrations of Dasatinib over 24 h (b). Interaction of HER2 and c-Src in SK-BR3 cells treated with the indicated concentrations of Dasatinib over
24 h (c)
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Furthermore, these ﬁndings correlate with a higher sen-
sitivity of BT474 cells to EGFR-targeted TKIs as indicated
by the reduction of cell viability after 24 h. There seems to
be a connection between the sensitivity of HER2-positive
cell lines to EGFR-targeted TKIs and the downstream
regulation of the interaction of PTPIP51 and c-Src.
Besides, the potential role of PTPIP51 in the sensitivity
of HER2-positive breast cancer cells to EGFR-targeted
TKIs, the selective recruitment to the HER2 receptor
points to a speciﬁc function of PTPIP51 in the changes of
cellular signaling induced by selective HER2 inhibition.
The selective recruitment is displayed by the unchanged
interaction of PTPIP51 and EGFR and the unchanged
heterodimer formation of the EGFR with HER2 in SK-
BR3 cells. As shown for the EGFR and dual speciﬁc TKIs,
Mubritinib showed an augmentation of PTPIP51/c-Src
interaction in SK-BR3 cells. Of note, the interaction of
PTPIP51 and c-Src gradually incremented in the same
stoichiometric proportion as the PTPIP51/HER2 inter-
action. This depicts a potential formation of a ternary
complex consisting of PTPIP51, HER2, and c-Src. This
ternary interaction was inﬂuenceable by the application of
the selective c-Src inhibitor Dasatinib. Interestingly,
Dasatinib induced the same shift of PTPIP51 toward the
HER2 receptor as seen for the application of the EGFR/
HER2-targeted TKIs. Furthermore, selective c-Src inhi-
bition also led to an increase in HER/c-Src interaction. All
these ﬁndings stress an important role of PTPIP51 in the
downstream regulations of the EGFR and HER2 signaling.
Beside its function in the MAPK pathway and EGFR
signaling, PTPIP51 is also involved in calcium home-
ostasis by arbitrating the contact of the mitochondrion to
the ER by the interaction with the ER bound protein
VAPB17. The tethering interaction of PTPIP51 and VAPB
is precisely regulated by the serine/threonine-kinase
GSK3β. The overexpression of GSK3β leads to an
impaired interaction of PTPIP51 and VAPB, whereas the
inhibition enhances the interaction18. Of note, mito-
chondrial metabolism assayed by a MTT test was sig-
niﬁcantly impaired under Mubritinib treatment using
10 µM of the inhibitor paralleled by a signiﬁcant reduction
of the PTPIP51/VAPB interaction, indicating the decay of
the MAMs in the SK-BR3 cell line. PTPIP51/GSK3β
interaction was signiﬁcantly enhanced under Mubritinib
treatment in SK-BR3 and BT474 cells. These ﬁndings are
not correlated to the observed PTPIP51/VAPB interaction
data. We assume, that the PTPIP51/VAPB interaction in
SK-BR3 and BT474 cells underlies various regulations and
is not only determined by the activity of GSK3β. Selective
inhibition of HER2 led to a signiﬁcantly increased inter-
action of PTPIP51 with GSK3β, Akt, and PKC in SK-BR3
and BT474 cells.
The group-based prediction system (GPS 3.0; http://
gps.biocuckoo.org/) identiﬁed PKC, Akt, and GSK3β to
phosphorylate PTPIP51 at Ser46, located in its conserved
region 1. Phosphorylation of Ser46 is the prerequisite for
the PTPIP51/14.3.3. complex formation7. Noteworthy,
the transmembrane domain of PTPIP51, which is
essential for the location to the mitochondrial membrane,
lies in direct vicinity to the conserved region 1. The
binding of 14.3.3 at conserved region 1 probably caps the
transmembrane domain of PTPIP51, thereby preventing
a translocation to the mitochondrial membrane30. This
could be a second potential regulation mechanism for
PTPIP51/VAPB interaction preventing mitochondrial
membrane translocation of PTPIP51 via 14.3.3 binding.
The precise regulation of the PTPIP51/VAPB complex
remains enigmatic and needs to be investigated in further
studies.
As a functional consequence, the loss of PTPIP51/
VAPB is a prerequisite for autophagy. Induction of
autophagy in MCF7 breast cancer cells leads to an
impaired survival, suggesting a potential tumor supportive
effect of autophagy31. Here, the PTPIP51/VAPB interac-
tion pattern may be predictive for a more aggressive
tumor biology.
As mentioned above, the interaction of PTPIP51 and
VAPB forms a physical tether between mitochondrion
and ER17. These contact sites, namely MAM, represent
important signaling hubs, e.g., for mTOR and Akt sig-
naling. The disruption of the MAMs leads to severe
alterations in the aforementioned signaling pathways and
the regulation of the calcium homeostasis between
mitochondrion and the ER32,33.
As seen here, that Akt signaling is activated under
selective HER2 inhibition in SK-BR3 cells as indicated by
the elevated S473 phosphorylation of Akt paralleled by a
reduced interaction of PTPIP51/VAPB. This activation of
Akt signaling is mediated through PTPIP51, as disclosed
in the knockdown experiments. The augmented Akt
phosphorylation at S473 might indicate an activation of
mTORC2 signaling34. In addition, activation of
mTORC2 signaling leads to an activation of PKC35. PKC
in turn can activate the MAPK pathway on Raf1 level36.
This cross-talk to MAPK signaling depicts a potential
explanation of MAPK signaling activation under selective
HER2 receptor inhibition. Still, the exact mechanism of
how the HER2-targeted TKI Mubritinib is capable of
altering the PTPIP51/VAPB interaction and the mTORC2
activity remains elusive and needs further investigations.
To sum up, PTPIP51 seems crucial for the downstream
regulations of EGFR/HER2-targeted TKIs. We showed,
that (1) PTPIP51/c-Src interaction is differently regulated
in SK-BR3 and BT474 cells correlating with their parti-
cular sensitivity to EGFR-targeted TKIs, (2) selective
inhibition of HER2 speciﬁcally recruited PTPIP51 to the
HER2 receptor and to c-Src reﬂecting a probable
mechanism for resistance, and (3) PTPIP51 is essential for
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the activation of Akt signaling under selective HER2
inhibition.
Materials and methods
Cell culture
We obtained the SK-BR3 cell line and the BT474 cell
line from Cell Line Service (Eppelheim, Germany). The
SK-BR3 cells were cultured in Dulbecco's MEM (Bio-
chrom) supplemented with 10% fetal calf serum and 1%
penicillin/streptomycin at 37 °C and 5% CO2 in a humi-
diﬁed chamber. BT474 cells were cultured in DMEM:
Hams F12 (1:1) supplemented with L-glutamine, Insulin
and FBS (Cell Lines Service, Eppelheim, Germany). The
medium was renewed every 2–3 days. They were cultured
until 70–80% conﬂuence. Cell harvesting was performed
with Accutase treatment for 10min in a humidiﬁed
chamber at 37 °C and 5% CO2. Subsequently, the cells
were rinsed with sterile phosphate-buffered saline (PBS)
and counted using a Neubauer counting chamber. The
cells were seeded at a density of 30,000–40,000 per well in
culture slides (Falcon CultureSlides, Corning Life Science,
New York, USA, Cat.# 354108). Mycoplasm infection was
excluded with 4′,6-diamidino-2-phenylindole (DAPI)
staining for each test.
shRNA experiments
shRNA constructs were obtained from Origene (Rock-
ville, MD, USA). SK-BR3 and BT474 cells were grown in
ﬂat-bottomed 24-well tissue culture plates for 24 h with a
starting cell number of 100,000 cells per well before
transfection. The provided shRNA constructs were initi-
ally dissolved in the supplied shRNA dilution buffer. For
shRNA experiments the transfection was performed using
Viromer Red (Lipocalyx GmbH, Halle, Germany, Cat.#
VR-01LB-01) according to the manufacturer’s protocol.
The shRNA constructs were diluted to a ﬁnal working
dilution of 1 ng/ml.
After transfection, cells were allowed to grow for
another 24 h. Transfection rate was controlled by mon-
itoring of expression of GFP via ﬂuorescence microscopy.
Transfected cells were incubated for another 24 h with the
indicated TKI. The reaction was terminated with
NuPAGE LDS Sample Buffer (Thermo Fischer Scientiﬁc,
Waltham, MA, USA).
Treatment
The cells were allowed to grow for 24 h after seeding.
Subsequently, they were treated with different concentra-
tions of Geﬁtinib (Biafﬁn, Kassel, Germany, Cat.# PKI-
GFTB2-200), Lapatinib (LC Laboratories, Woburn, USA,
Cat.# L-4804), Neratinib (LC Laboratories, Woburn,
USA, Cat.# L-6404), Mubritinib (Selleckchem, Munich,
Germany, Cat.# S2216), or Dasatinib (LC Laboratories,
Woburn, USA, Cat.# D-3307) for either 24 h or 48 h.
Immunocytochemistry
The slides were washed in PBS two times for 5 min.
After ﬁxation in cold Methanol for 10min, the slides were
washed again in PBS for 8 min. The primary antibodies
were diluted in blocking solution to the concentration as
reported in Supplementary Table 1. After incubation at
room temperature overnight under continuous move-
ment in a humidiﬁed chamber, the slides were washed 3 ×
in PBS for 10min. The secondary antibodies were diluted
(Supplementary Table 1) in PBS and 10% DAPI was
added. The samples were incubated for 45min in a
humidiﬁed chamber at room temperature in the dark.
After washing 3 × in PBS for 10min the slides were
mounted with Mowiol and stored at 4 °C until
examination.
Duolink proximity ligation assay
To determine the interactions of proteins the Duolink
Proximity ligation assay (PLA probe anti-rabbit minus,
Cat.# 92005, PLA probe anti-mouse plus, Cat.# 92001;
Detection Kit Orange, Cat.# 92007) was used. The assay is
based on the binding of PLA probes to the primary
antibodies. If these are closer than 40 nm a signal is
generated. After washing the ﬁxed SK-BR3 cells 10 min in
PBS the primary antibodies diluted in blocking solution
were applied (concentrations in Supplementary Table 1).
The slides were allowed to incubate overnight in a
humidiﬁed chamber under continuous movement. The
primary antibodies were tapped off and the slides were
washed in PBS 2 × 10 min. PLA probes detecting mouse
(Cat# 92001–0100), goat (Cat# 92003–0100), and rabbit
antibodies (Cat# 92005–0100) were diluted (1:5) in PBS.
Slides were incubated at 37 °C in a humidiﬁed chamber
for 1 h. The excess amount of PLA probes was tapped off
and the samples were washed in Wash-Buffer A 2 ×
10min. Duolink II Ligation stock (1:5) and Duolink Ligase
(1:40) were diluted in high purity water and added to the
slides. After incubation for 30min in a humidiﬁed
chamber at 37 °C, the solution was tapped off and the
slides were washed in Wash-Buffer A 2 × 5min. Duolink
Polymerase (1:80) and Duolink Ampliﬁcation and
Detection stock (1:5) were diluted in high purity water
and added to the samples. The slides were allowed to
incubate for 100min in a humidiﬁed chamber at 37 °C in
the dark. Finally, the slides were washed 2 × in Wash-
Buffer B for 10min and 1 × in 0.01 × Wash-Buffer B for
1 min. Nuclear staining was performed using DAPI. After
drying for 30min at room temperature in the dark they
were mounted with Mowiol and stored at 4 °C until
examination. Leuchowius et al.37 identiﬁed the Duolink
proximity ligation assay as an adequate tool for identiﬁ-
cation of small molecule effectors for protein–protein
interactions.
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Fluorescence microscopy
The photo documentation was performed with Axio-
plan 2 ﬂuorescence microscope equipped with Plan-
Apochromat objectives (Carl Zeiss Jena, Jena, Germany).
Protein interaction analysis
For quantiﬁcation, the DuoLink Image Tool (Olink
Bioscience, Uppsala, Sweden, v1.0.1.2) was applied. The
software identiﬁes DAPI-positive nuclei for the cell count.
Cell borders were set according to the software calculated
cell shape using a user deﬁned cell diameter preset.
Fluorescence dots of the DPLA were counted by the
software for each single marked cell.
Western blot
Samples of SK-BR-3 cell lysates were separated on
Mini-PROTEAN TGX Stain-Free Precast Gels (Bio-Rad,
München, Germany Cat.# 4568085). The Bio-Rad Trans-
Blot Turbo Transfer System (Bio-Rad, München, Ger-
many) with the settings for mixed molecular weight
proteins was used for transfer to an Immobilon-P mem-
brane (Millipore, Billerica, USA, Cat.#IPVH07850)
according to manufacturer’s instructions. The membrane
was blocked with 1 × Rotiblock for 1 h h at room tem-
perature. Incubation with anti-pMAPK or anti-Akt was
done overnight at 4 °C. Horseradish peroxidase-
conjugated anti-rabbit immunoglobulins diluted in 1 ×
Rotiblock were applied for 1 h at room temperature. The
reaction was visualized with the ECL prime substrate. The
Bio-Rad ChemiDoc Touch Imaging System (Bio-Rad,
München, Germany) was used for documentation. Cali-
bration was performed with a molecular weight marker
suitable for chemiluminescence (Life Technologies
GmbH, Darmstadt, Germany, Cat.# LC5602). The blots
were equalized to the obtained stain-free blot for com-
parison using the Bio-Rad Image Lab (Bio-Rad, München,
Germany). Hence, no loading control is required.
MTT assay
The cells were seeded in a 96-well plate at a density of
10,000 cells per well and were allowed to grow for 24 h.
The treatment of the cells was carried out as indicated.
The MTT solution was added 4 h before the end of the
incubation time. After formation of the formazan crystals,
the solubilization solution (10% sodium dodecyl sulphate
in 0.01M HCl) was added. The solution was carried out
overnight in a 37 °C 5% CO2 humidiﬁed chamber. Eva-
luation of the assay was performed with Berthold Tech
TriStar ELISA Reader (Bad Wildbad, Germany).
Statistical analysis
The data were evaluated using GraphPad Prism 6 soft-
ware. For variance analysis One way analysis of variance
tests were performed. Statistical testing was done using
the Dunnett’s multiple comparison test in case of Gaus-
sian distribution. Otherwise, Dunn’s multiple comparison
was used. Results were considered signiﬁcant with
p < 0.05. (*(p < 0.05), **(p < 0.01), ***(p < 0.001),
****(p < 0.0001))
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